BC Innovations | Jun 20, 2019
Distillery Therapeutics

MHCII nanoparticles for autoimmune hepatic diseases

DISEASE CATEGORY: Hepatic INDICATION: Cirrhosis; hepatitis; liver disease A team led by Parvus Therapeutics Inc. founder Pere Santamaria has developed nanoparticles coated with MHCII molecules displaying a PDH-derived epitope associated with primary biliary cholangitis (PBC)...
BC Innovations | Feb 8, 2019
Product R&D

Reducing R(i)SK in TNBC

Phoenix Molecular Designs could provide triple-negative breast cancer its first molecular marker to turn the intractable indication from a group of have-nots to a group of haves. With early evidence that RSK2 is activated in...
BC Innovations | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
BioCentury | Oct 20, 2018
Product Development

CVOT damage in diabetes

As FDA reconsiders its requirement for cardiovascular outcomes trials of new diabetes candidates, it’s clear that the development of new therapies has slowed since it was implemented. In December 2008, FDA issued guidance requiring diabetes...
BC Innovations | Apr 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: March 2018

New Therapeutic Targets and Biomarkers: March 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March 2018. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Mar 13, 2018
Distillery Therapeutics


INDICATION: Prostate cancer Cell culture and mouse studies suggest inhibiting PDHA1 could help treat prostate cancer. In tumor samples from patients, levels of PDHA1 were higher than in normal prostate tissue. In three human prostate...
BC Week In Review | Apr 7, 2017
Clinical News

CPI-613 regulatory update

Based on an end-of-Phase I meeting with FDA, Cornerstone said it plans to advance lead candidate CPI-613 directly from Phase I testing into pivotal trials. This year, the company plans to start 2 pivotal trials...
BioCentury | Mar 25, 2017
Product Development

Pivotal meeting

Cornerstone Pharmaceuticals Inc. was planning a traditional development pathway for CPI-613 in acute myelogenous leukemia and pancreatic cancer, but FDA nudged the company to go from Phase I to pivotal trials for both indications. According...
BC Extra | Mar 23, 2017
Company News

Cornerstone to start pivotal trials in AML, pancreatic cancer

Cornerstone Pharmaceuticals Inc. (Cranbury, N.J.) plans to start two pivotal studies this year of lead candidate CPI-613 to treat relapsed/refractory acute myelogenous leukemia (AML) patients aged 60 and older and stage IV pancreatic cancer patients....
BC Innovations | Aug 18, 2016
Distillery Therapeutics

Therapeutics: Phosphoinositide 3-kinase α (PI3Kα); pyruvate dehydrogenase kinase 1 (PDK1); serum/glucocorticoid regulated kinase 1 (SGK1)

Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting PDK1 or SGK1 could help treat PI3Kα inhibitor-resistant breast cancer. In breast cancer patients, high tumor expression of SGK1 correlated with resistance...
Items per page:
1 - 10 of 42